Enanta Pharmaceuticals Inc Market Cap ($303.78 Million)
Market Cap & Net Worth: Enanta Pharmaceuticals Inc (ENTA)
Enanta Pharmaceuticals Inc market cap. Enanta Pharmaceuticals Inc (NASDAQ:ENTA) has a market capitalization of $303.78 Million ($303.78 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #14469 globally and #3457 in its home market, demonstrating a -10.40% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Enanta Pharmaceuticals Inc's stock price $10.43 by its total outstanding shares 29125402 (29.13 Million). Also see Enanta Pharmaceuticals Inc cash flow conversion for how efficiently the company converts equity into cash flow.
Enanta Pharmaceuticals Inc Market Cap History (2015–2026)
Enanta Pharmaceuticals Inc market cap history from 2015 to 2026. Data shows change from $961.72 Million to $303.78 Million (-11.53% CAGR). Check Enanta Pharmaceuticals Inc share price for real-time trading data and today's change.
Index Memberships
Enanta Pharmaceuticals Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.60 Trillion | 0.01% | #383 of 976 |
|
NASDAQ Composite
IXIC
|
$39.84 Trillion | 0.00% | #1412 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.83 Trillion | 0.02% | #202 of 263 |
Weight: Enanta Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Enanta Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Enanta Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore ENTA shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
7.03x
Enanta Pharmaceuticals Inc's market cap is 7.03 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $975.70 Million | $88.27 Million | $21.67 Million | 11.05x | 45.03x |
| 2017 | $1.71 Billion | $102.81 Million | $17.71 Million | 16.62x | 96.50x |
| 2018 | $2.06 Billion | $206.62 Million | $71.96 Million | 9.98x | 28.67x |
| 2019 | $1.80 Billion | $205.20 Million | $46.38 Million | 8.77x | 38.79x |
| 2020 | $1.23 Billion | $122.47 Million | -$36.17 Million | 10.01x | N/A |
| 2021 | $2.18 Billion | $97.07 Million | -$79.00 Million | 22.44x | N/A |
| 2022 | $1.35 Billion | $86.16 Million | -$121.75 Million | 15.73x | N/A |
| 2023 | $274.07 Million | $79.20 Million | -$133.82 Million | 3.46x | N/A |
| 2024 | $167.47 Million | $67.64 Million | -$116.05 Million | 2.48x | N/A |
| 2025 | $459.31 Million | $65.32 Million | -$81.89 Million | 7.03x | N/A |
Competitor Companies of ENTA by Market Capitalization
Companies near Enanta Pharmaceuticals Inc in the global market cap rankings as of November 4, 2026. Also see ENTA asset base for a full breakdown of the balance sheet.
Key companies related to Enanta Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of Enanta Pharmaceuticals Inc (2015–2026)
Market capitalization of Enanta Pharmaceuticals Inc from 2015 to today. Between 2015 and today, Enanta Pharmaceuticals Inc's market cap moved from $961.72 Million to $ 303.78 Million, with a yearly change of -11.53%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $303.78 Million | -33.86% |
| 2025 | $459.31 Million | +174.26% |
| 2024 | $167.47 Million | -38.89% |
| 2023 | $274.07 Million | -79.77% |
| 2022 | $1.35 Billion | -37.79% |
| 2021 | $2.18 Billion | +77.62% |
| 2020 | $1.23 Billion | -31.85% |
| 2019 | $1.80 Billion | -12.78% |
| 2018 | $2.06 Billion | +20.71% |
| 2017 | $1.71 Billion | +75.16% |
| 2016 | $975.70 Million | +1.45% |
| 2015 | $961.72 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Enanta Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $303.78 Million USD |
| MoneyControl | $303.78 Million USD |
| MarketWatch | $303.78 Million USD |
| marketcap.company | $303.78 Million USD |
| Reuters | $303.78 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Enanta Pharmaceuticals Inc
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respirato… Read more